Biotech Innovators: How it Started

Learning How Targeting Dark Matter Helps Develop Fibrotic Disease Treatment

Thermo Fisher Scientific Season 1 Episode 1

We're living during a time of enormous technological breakthroughs and innovation is the key to shaping the world. 

However, when it comes to the biotech industry and biotechnological drug development,  science has to always be at the center of them.

In this episode of the Biotech Innovators podcast, we welcome Samir Ounzain, the co-founder & CEO of Haya Therapeutics. They talk about Samir's path from watching Jurassic Park in a dark theater as a kid to studying the dark matter of the human genome in a lab – and eventually, to the founding of Haya Therapeutics.



This content is offered for informational purposes only. The opinions stated in this podcast are that of the speaker and do not constitute or imply an endorsement by Thermo Fisher Scientific.